Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Forum Dermatologicum
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

Vol 6, No 3 (2020)
Review paper
Published online: 2020-09-30
Add to basket: 49.00 PLN
Get Citation

Risk of cancers in patients with mastocytosis

Maciej Milewczyk1, Michał Joskowski1, Justyna Czarny2, Magdalena Lange2
DOI: 10.5603/FD.2020.0013
·
Forum Dermatologicum 2020;6(3):77-81.
Affiliations
  1. University Clinical Center Department of Oncology and Radiotherapy, Gdańsk, Poland
  2. Katedra i Klinika Dermatologii, Wenerologii i Alergologii, Gdański Uniwersytet Medyczny, Gdańsk

paid access

Vol 6, No 3 (2020)
REVIEW ARTICLES
Published online: 2020-09-30

Abstract

Mastocytosis is a heterogeneous disease characterized by clonal proliferation and abnormal mast cells accumulation in various tissues, particularly in the skin and bone marrow. The clinical spectrum of systemic mastocytosis (SM) includes, among others, SM with associated hematologic neoplasm (SM-AHD) and mast cell leukemia (MCL). However, little is known about the incidence and pathogenesis of non-hematological malignancies in patients with mastocytosis. Increased risk of carcinogenesis in this group of patients could be associated with treatment methods of this disease. PUVA-therapy, as one of cutaneous mastocytosis (CM) treatment options, and the influence of immunosuppression and cytoreductive treatment in advanced forms of SM may influence carcinogenesis. According to the recent publications, increased risk of malignant neoplasms of the skin and internal organs in patients with mastocytosis has been observed. The current state of knowledge suggests a holistic approach and the need of oncological assessment of mastocytosis patients, particularly as far as malignant melanoma is concerned.

Abstract

Mastocytosis is a heterogeneous disease characterized by clonal proliferation and abnormal mast cells accumulation in various tissues, particularly in the skin and bone marrow. The clinical spectrum of systemic mastocytosis (SM) includes, among others, SM with associated hematologic neoplasm (SM-AHD) and mast cell leukemia (MCL). However, little is known about the incidence and pathogenesis of non-hematological malignancies in patients with mastocytosis. Increased risk of carcinogenesis in this group of patients could be associated with treatment methods of this disease. PUVA-therapy, as one of cutaneous mastocytosis (CM) treatment options, and the influence of immunosuppression and cytoreductive treatment in advanced forms of SM may influence carcinogenesis. According to the recent publications, increased risk of malignant neoplasms of the skin and internal organs in patients with mastocytosis has been observed. The current state of knowledge suggests a holistic approach and the need of oncological assessment of mastocytosis patients, particularly as far as malignant melanoma is concerned.

Full Text:

Add to basket: 49.00 PLN
Get Citation

Keywords

mastocytosis; cancers; melanoma malignum

About this article
Title

Risk of cancers in patients with mastocytosis

Journal

Forum Dermatologicum

Issue

Vol 6, No 3 (2020)

Article type

Review paper

Pages

77-81

Published online

2020-09-30

Page views

911

Article views/downloads

44

DOI

10.5603/FD.2020.0013

Bibliographic record

Forum Dermatologicum 2020;6(3):77-81.

Keywords

mastocytosis
cancers
melanoma malignum

Authors

Maciej Milewczyk
Michał Joskowski
Justyna Czarny
Magdalena Lange

References (28)
  1. Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood. 2017; 129(11): 1420–1427.
    CrossRefPubMed
  2. Valent P, Akin C, Escribano L, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007; 37(6): 435–453.
    CrossRefPubMed
  3. Pardanani A. Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol. 2019; 94(3): 363–377.
    CrossRefPubMed
  4. Lange M, Flisiak I, Kapinska-Mrowiecka ML, et al. Mastocytosis. Diagnostic and therapeutic recommendations of the Polish Dermatological Society. Przegl Dermatol. 2018; 105(3): 358–383.
  5. Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol. 2016; 137(1): 35–45.
    CrossRefPubMed
  6. Valent P, Akin C, Gleixner KV, et al. Multidisciplinary challenges in mastocytosis and how to address with personalized medicine approaches. Int J Mol Sci. 2019; 20(12).
    CrossRefPubMed
  7. Broesby-Olsen S, Dybedal I, Gülen T, et al. Multidisciplinary management of mastocytosis: Nordic Expert Group consensus. Acta Derm Venereol. 2016; 96(5): 602–612.
    CrossRefPubMed
  8. Wagner N, Staubach P. Mastocytosis - pathogenesis, clinical manifestation and treatment. J Dtsch Dermatol Ges. 2018; 16(1): 42–57.
    CrossRefPubMed
  9. Czarny J, Lange M, Ługowska-Umer H, et al. Cutaneous mastocytosis treatment: strategies, limitations and perspectives. Postepy Dermatol Alergol. 2018; 35(6): 541–545.
    CrossRefPubMed
  10. Siebenhaar F, Akin C, Bindslev-Jensen C, et al. Treatment strategies in mastocytosis. Immunol Allergy Clin North Am. 2014; 34(2): 433–447.
    CrossRefPubMed
  11. Obtułowicz A, Pirowska MM, Woźniacka A, et al. Suitability of tryptase concentration determination during PUVA therapy in patients with cutaneous and systemic mastocytosis. Przegl Dermatol. 2018; 105(1): 41–50.
  12. Siiskonen H, Smorodchenko A, Krause K, et al. Ultraviolet radiation and skin mast cells: Effects, mechanisms and relevance for skin diseases. Exp Dermatol. 2018; 27(1): 3–8.
    CrossRefPubMed
  13. Brazzelli V, Grassi S, Merante S, et al. Narrow-band UVB phototherapy and psoralen-ultraviolet A photochemotherapy in the treatment of cutaneous mastocytosis: a study in 20 patients. Photodermatol Photoimmunol Photomed. 2016; 32(5-6): 238–246.
    CrossRefPubMed
  14. Placek W, Kaszuba A, Lesiak A, et al. Phototherapy and photochemotherapy in dermatology. Recommendations of the Polish Dermatological Society. Dermatology Review. 2019; 106(3): 237–256.
    CrossRef
  15. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet. 1998; 351(9103): 623–628.
    CrossRefPubMed
  16. Vajdic CM, van Leeuwen MT. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer. 2009; 125(8): 1747–1754.
    CrossRefPubMed
  17. Wimmer CD, Rentsch M, Crispin A, et al. The janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int. 2007; 71(12): 1271–1278.
    CrossRefPubMed
  18. Broesby-Olsen S, Farkas DK, Vestergaard H, et al. Risk of solid cancer, cardiovascular disease, anaphylaxis, osteoporosis and fractures in patients with systemic mastocytosis: A nationwide population-based study. Am J Hematol. 2016; 91(11): 1069–1075.
    CrossRefPubMed
  19. Molderings GJ, Zienkiewicz T, Homann J, et al. Risk of solid cancer in patients with mast cell activation syndrome: Results from Germany and USA. F1000Res. 2017; 6: 1889.
    CrossRefPubMed
  20. Wilcock A, Bahri R, Bulfone-Paus S, et al. Mast cell disorders: From infancy to maturity. Allergy. 2019; 74(1): 53–63.
    CrossRefPubMed
  21. Kopeć-Szlęzak J. Mastocyty i ich znaczenie w procesach odpornościowych i nowotworowych. J Transf Med. 2015; 8: 49–59.
  22. Tóth-Jakatics R, Jimi S, Takebayashi S, et al. Cutaneous malignant melanoma: correlation between neovascularization and peritumor accumulation of mast cells overexpressing vascular endothelial growth factor. Hum Pathol. 2000; 31(8): 955–960.
    CrossRefPubMed
  23. Todd P, Garioch J, Seywright M, et al. Malignant melanoma and systemic mastocytosis--a possible association? Clin Exp Dermatol. 1991; 16(6): 455–457.
    CrossRefPubMed
  24. Okun M, Bhawan J. Combined melanocytoma-mastocytoma in a case of nodular mastocytosis. Journal of the American Academy of Dermatology. 1979; 1(4): 338–347.
    CrossRef
  25. Hägglund H, Sander B, Gülen T, et al. Increased risk of malignant melanoma in patients with systemic mastocytosis? Acta Derm Venereol. 2014; 94(5): 583–584.
    CrossRefPubMed
  26. Donati P, Paolino G, Donati M, et al. Cutaneous mastocytosis combined with eruptive melanocytic nevi and melanoma. Coincidence or a linkage in the pathogenesis? J Dermatol Case Rep. 2014; 8(3): 70–74.
    CrossRefPubMed
  27. Longley BJ, Morganroth GS, Tyrrell L, et al. Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis . New Engl J Med. 1993; 18(328): 1302–1307.
    CrossRefPubMed
  28. Vojvodic A, Vlaskovic-Jovicevic T, Vojvodic P, et al. Melanoma and mastocytosis. Open Access Maced J Med Sci. 2019; 7(18): 3050–3052.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
phone: +48 58 320 94 94, fax: +48 58 320 94 60, e-mail: viamedica@viamedica.pl